A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2018
At a glance
- Drugs Atacicept (Primary)
- Indications IgA nephropathy; Proteinuria
- Focus Adverse reactions; Therapeutic Use
- 11 Apr 2018 Planned primary completion date changed from 17 Aug 2020 to 30 Jul 2020.
- 20 Mar 2018 Planned number of patients changed from 100 to 30.
- 16 Jan 2018 Planned End Date changed from 17 Jan 2020 to 17 Aug 2022.